Woodline Partners LP Boosts Stake in Pfizer Inc. (NYSE:PFE)

Woodline Partners LP grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,318,490 shares of the biopharmaceutical company's stock after acquiring an additional 191,957 shares during the quarter. Woodline Partners LP's holdings in Pfizer were worth $34,980,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Parsons Capital Management Inc. RI raised its holdings in Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Mcdonald Partners LLC raised its stake in shares of Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after acquiring an additional 9,963 shares in the last quarter. Bank of Jackson Hole Trust purchased a new stake in Pfizer during the fourth quarter valued at approximately $264,000. Amplius Wealth Advisors LLC boosted its stake in Pfizer by 80.7% in the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company's stock valued at $1,242,000 after acquiring an additional 20,911 shares in the last quarter. Finally, Harvey Capital Management Inc. purchased a new position in Pfizer in the fourth quarter worth $544,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Performance

PFE opened at $23.51 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a 50 day moving average of $23.56 and a two-hundred day moving average of $25.27. The firm has a market capitalization of $133.66 billion, a PE ratio of 16.67, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.